nanoliposomal irinotecan + oxaliplatin + capecitabine

This is a combination chemotherapy regimen consisting of nanoliposomal irinotecan, oxaliplatin, and capecitabine. Nanoliposomal irinotecan is a liposome-encapsulated formulation of irinotecan that inhibits topoisomerase I, leading to DNA damage and apoptosis in cancer cells[6]. Oxaliplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks and inhibits DNA synthesis. Capecitabine is an oral prodrug converted to 5-fluorouracil (5-FU) preferentially in tumor tissue, inhibiting thymidylate synthase and interfering with DNA synthesis[1][2][3]. This triplet regimen aims to combine the efficacy of these agents for enhanced antitumor activity while potentially improving patient convenience by substituting continuous infusion 5-FU with oral capecitabine[1][3].

Other names

Nanoliposomal Irinotecan, Oxaliplatin plus CapecitabineNanoliposomal Irinotecan + Oxaliplatin + Capecitabine